Inequities Associated With Advanced Stage at Presentation of Head and Neck Cancer

被引:2
|
作者
Ioerger, Patrick [1 ]
Mills, Kale [2 ]
Wagoner, Sarah F. [3 ]
Lawrence, Amelia [3 ]
Alapati, Rahul [3 ]
Nallani, Rohit [3 ]
Hamill, Chelsea S. [3 ]
Boakye, Eric Adjei [4 ,5 ]
Sykes, Kevin J. [1 ,6 ]
机构
[1] Univ Kansas, Sch Med, Kansas City, MO USA
[2] Univ Kansas, Sch Med Wichita, Wichita, KS USA
[3] Univ Kansas Med Ctr, 3901 Rainbow Blvd,Mailstop 3010, Kansas City, KS 66160 USA
[4] Henry Ford Hlth, Dept Publ Hlth Sci, Detroit, MI USA
[5] Henry Ford Hlth, Dept Otolaryngol Head & Neck Surg, Detroit, MI USA
[6] Baylor Scott & White Hlth & Wellness Ctr, Dallas, TX USA
关键词
SQUAMOUS-CELL CARCINOMA; LARYNGEAL-CANCER; RACIAL DISPARITIES; SURVIVAL OUTCOMES; DIAGNOSIS; IMPACT; DETERMINANTS; METASTASIS; DELAYS; RISK;
D O I
10.1001/jamaoto.2024.1180
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Importance Social determinants of health (SDoH) are defined by a wide range of factors (eg, built environment, economic stability, education level, discrimination, racism, access to health care). Advanced stage at presentation or delayed diagnosis heavily influences health outcomes in patients with head and neck cancer (HNC). While the drivers of advanced-stage presentation come from a multitude of sources, SDoH plays an outsized role. Objective To systematically review the published literature to identify which SDoH are established as risk factors for delayed diagnosis or advanced stage at presentation among patients with HNC. Evidence Review In this systematic review, a literature search of PubMed, Web of Science, and Embase was conducted on February 27, 2023, using keywords related to advanced stage at presentation and delayed diagnosis of HNC between 2013 and 2023. Quality assessment was evaluated through the Newcastle-Ottawa Scale. Articles were included if they focused on US-based populations and factors associated with advanced stage at presentation or delayed diagnosis of HNC. Findings Overall, 50 articles were included for full-text extraction, of which 30 (60%) were database studies. Race was the most commonly reported variable (46 studies [92%]), with Black race (43 studies [93%]) being the most studied racial group showing an increased risk of delay in diagnosis of HNC. Other commonly studied variables that were associated with advanced stage at presentation included sex and gender (41 studies [82%]), insurance status (25 studies [50%]), geographic region (5 studies [10%]), and socioeconomic status (20 studies [40%]). Male sex, lack of insurance, rurality, and low socioeconomic status were all identified as risk factors for advanced stage at presentation. Conclusions and Relevance This systematic review provides a comprehensive list of factors that were associated with advanced HNC stage at presentation. Future studies should focus on evaluating interventions aimed at addressing the SDoH in communities experiencing disparities to provide a net positive effect on HNC care.
引用
收藏
页码:727 / 740
页数:14
相关论文
共 50 条
  • [31] TREATMENT OF THE CLINICALLY NEGATIVE NECK IN ADVANCED CANCER OF THE HEAD AND NECK
    WEISSLER, MC
    WEIGEL, MT
    ROSENMAN, JG
    SILVER, JR
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1989, 115 (06) : 691 - 694
  • [32] Radiofrequency Ablation of Advanced Head and Neck Cancer
    Owen, Randall P.
    Khan, Sajid A.
    Negassa, Abdissa
    Beitler, Jonathan J.
    Bello, Jacqueline A.
    Brook, Allan
    Farinhas, Joaquim
    Garg, Madhur K.
    Haigentz, Missak, Jr.
    Miller, Todd S.
    Hsu, Melody S.
    Ravikumar, Thanjuvar S.
    Shifteh, Keivan
    Smith, Richard V.
    Silver, Carl E.
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2011, 137 (05) : 493 - 498
  • [33] Radiofrequency ablation in advanced head and neck cancer
    Owen, Randall P.
    Lee, Jane S.
    Silver, Carl E.
    Back, Leif
    Beitler, Jonathan J.
    Rinaldo, Alessandra
    O'Malley, Bert W., Jr.
    Haigentz, Missak, Jr.
    Ferlito, Alfio
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2014, 271 (02) : 207 - 210
  • [34] BNCT for advanced or recurrent head and neck cancer
    Aihara, Teruhito
    Morita, Norimasa
    Kamitani, Nobuhiko
    Kumada, Hiroaki
    Ono, Koji
    Hiratsuka, Junichi
    Harada, Tamotsu
    APPLIED RADIATION AND ISOTOPES, 2014, 88 : 12 - 15
  • [35] Chemoradiotherapy for locally advanced head and neck cancer
    Salama, Joseph K.
    Seiwert, Tanguy Y.
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) : 4118 - 4126
  • [36] Gemcitabine in the treatment of advanced head and neck cancer
    Raguse, JD
    Gath, HJ
    Bier, J
    Riess, H
    Oettle, H
    CLINICAL ONCOLOGY, 2005, 17 (06) : 425 - 429
  • [37] Therapy for locoregionally advanced head and neck cancer
    Vokes, EE
    SEMINARS IN RADIATION ONCOLOGY, 1997, 7 (03) : 4 - 7
  • [38] Prognostic factors in advanced head and neck cancer
    Kessing, Richard
    LARYNGO-RHINO-OTOLOGIE, 2024, 103 (06) : 397 - 398
  • [39] PREOPERATIVE CHEMOTHERAPY IN ADVANCED CANCER OF THE HEAD AND NECK
    SPAULDING, MB
    KLOTCH, D
    LORE, JM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 403 - 403
  • [40] Treatment of advanced head and neck cancer - Reply
    Bernier, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08): : 830 - 831